• 1
    Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 188204.
  • 2
    Snow V, Qaseem A, Barry P, Hornbake ER, Rodnick JE, Tobolic T, Ireland B, Segal JB, Bass EB. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the Academy of Family Physicians. Ann Intern Med 2007; 146: 20410.
  • 3
    Pfizer Australia Pty Ltd. Product Information. Fragmin® Injection. Dalteparin sodium. 2006. Available at (last accessed 1 November 2008).
  • 4
    Sanofi-Aventis Australia Pty Ltd. Clexane® Product Information. 2008. Available at (last accessed 1 November 2008).
  • 5
    Datapharm communications Ltd. The electronic Medicines Compendium. 2008. Available at (last accessed 1 November 2008).
  • 6
    MEDSAFE. New Zealand medicines and medical devices safety authority. 2008. Available at (last accessed 1 November 2008).
  • 7
    FDA. U.S. Food and Drug Administration. 2008. Available at (last accessed 1 November 2008).
  • 8
    Green B, Greenwood M, Saltissi D, Westhuyzen J, Kluver L, Rowell J, Atherton J. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2004; 59: 28190.
  • 9
    Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003; 54: 96103.
  • 10
    Antman EM, McCabe C, Gurfinkel E, Turpie A, Alexander G, Bernink P, Salein D, De Luna A, Fox K, LaBlanche J-M, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593601.
  • 11
    Cohen M, Demers C, Gurfinkel E, Turpie A, Fromell G, Goodman S, Langer A, Califf R, Fox K, Premmereur J, Bigonzi F, Stephens J, Weatherley B. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 44752.
  • 12
    Klein W, Buchwald A, Hills S, Monrad S, Sanz G, Turpie A, Van der Meer J, Olaisson E, Underland S, Ludwig K. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96: 618.
  • 13
    World Health Organisation. Obesity and overweight. What are overweight and obesity? 2007. Available at (last accessed 3 July 2008).
  • 14
    Barsoum R. Chronic kidney disease in the developing world. N Engl J Med 2006; 354: 99799.
  • 15
    Checkbox survey solutions. Checkbox Survey Software®. 2007. Available at (last accessed 7 December 2008).
  • 16
    The Society of Hospital Pharmacists of Australia. SHPA directory of hospital pharmacy. 2007. Available at (last accessed 28 August 2008).
  • 17
    New Zealand HealthCare Pharmacists' Association. New Zealand Hospital Pharmacies 2008. 2008. Available at (last accessed 28 August 2008).
  • 18
    United Kingdom Medical Information Pharmacists. Medical information Pharmacist directory. 2008. Available at (last accessed 28 October 2008).
  • 19
    Koumis T, Cicero L, Nathan J, Rosenberg J. Directory of pharmacist-operated drug information centers in the United States-2003. Am J Health Syst Pharm 2003; 61: 203342.
  • 20
    CAMIPR. Consortium for the advancement of medication information, policy and research. Listserver. 2007. Available at (last accessed 15 October 2008).
  • 21
    Janmahasatian S, Duffull SB, Chagnac A, Kirkpatrick CMJ, Green B. Lean body mass normalizes the effect of obesity on renal function. Br J Clin Pharmacol 2008; 65: 96465.
  • 22
    Han P, Duffull SB, Kirkpatrick CMJ, Green B. Dosing in obesity: a simple solution to a big problem. Clin Phamacol Ther 2007; 82: 50508.
  • 23
    Green B, Duffull S. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 11933.
  • 24
    Gouin-Thibault I, Pautas E, Mahe I, Descarpentries C, Nivet-Antoine V, Golmard J-L, Siguret V. Is modification of diet in renal disease formula similar to Cockcroft-Gault formula to assess renal function in elderly hospitalized patients treated with low-molecular-weight heparin? J Gerontol 2007; 62A: 130005.
  • 25
    Melloni C, Peterson E, Chen A, Szczech L, Newby L, Harrington R, Gibler W, Ohman E, Spinler S, Roe M, Alexander K. Cockcroft-Gault versus modification of diet in renal disease. J Am Coll Cardiol 2008; 51: 9916.
  • 26
    Moranville M, Jennings H. Implications of using modification of diet in renal disease Cockcroft-Gault equations for renal dosing adjustments. Am J Health Syst Pharm 2009; 66: 15461.
  • 27
    Vats V, Nutescu E, Theobald J, Wojtynek J, Schumock G. Survey of hospital guidelines, policies, and protocols for anticoagulants. Am J Health Syst Pharm 2007; 64: 12038.
  • 28
    Nutescu E, Lewis R, Finley J, Schumock G. Hospital guidelines for use of low-molecular-weight heparins. Ann Pharmacother 2003; 37: 107281.
  • 29
    Hull R. Treatment of pulmonary embolism: the use of low-molecular-weight heparin in the inpatient and outpatient settings. Thromb Haemost 2008; 99: 50210.
  • 30
    Merli G, Spiro T, Olsson C, Abildgaard U, Davidson B, Eldor A, Elias D, Grigg A, Musset D, Rodgers G, Trowbridge A, Yusen R, Zawilska K. Subcutaneous enoxaparin once or twice daily compared with intravenous heparin for the treatment of venous thromboembolic disease. Ann Intern Med 2001; 134: 191202.
  • 31
    Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: Low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 67384.
  • 32
    Fox K, Antman E, Montalescot G, Agewall S, SomaRaju B, Verheugt F, Lopez-Sendon J, Hod H, Murphy S, Braunwald E. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007; 49: 224955.
  • 33
    Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 34
    Cheymol G. Effects of obesity on pharmacokinetics. Implications for drug therapy. Clin Pharmacokinet 2000; 39: 21531.
  • 35
    Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 105165.
  • 36
    Moscucci M, Fox KA, Cannon CO, Klein W. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE). Eur Heart J 2003; 24: 181523.
  • 37
    U.S. Food and Drug Administration. Communication about ongoing safety review. Innohep (tinzaparin sodium injection). 2008. Available at (last accessed 24 April 2009).
  • 38
    Thrombolysis in Myocardial Infarction (TIMI)11A Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997; 29: 147482.
  • 39
    Montalescot G, Collet J, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004; 110: 39298.
  • 40
    Collet J, Montalescot G, Fine E, Golmard J-L. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003; 41: 814.
  • 41
    Hulot J-S, Montalescot G, Lechat P, Collet J-P, Ankri A, Urien S. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005; 77: 54252.
  • 42
    Spinler S, Ou F-S, Roe MT, Gibler WB, Ohman EM, Pollack CV, Alexander K, Peterson ED. Weight-based dosing of enoxaparin in obese patients with non-ST-elevation acute coronary syndromes: results from the CRUSADE initiative. Pharmacotherapy 2009; 29: 63138.
  • 43
    Barras MA, Duffull SB, Atherton JJ, Green B. Individualized compared to conventional dosing of enoxaparin. Clin Pharmacol Ther 2008; 83: 88288.